CLEAR LABELS Act
- Bill Number
- S. 3788
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- Last Updated
- 2026-05-01T18:56:32Z
AI-Generated Summary
Purpose
The CLEAR LABELS Act aims to increase transparency in the pharmaceutical supply chain by requiring drug labels to disclose information about original manufacturers and key supply chain entities. This helps consumers and regulators trace the origins of drugs, potentially improving safety and accountability.
Key Provisions
- Labeling Requirements for All Drugs: Drug packages must include the name, place of business, and unique facility identifier (a specific code identifying the production site) of the manufacturer, packer, or distributor. Alternatively, a link, barcode, QR code, or other tool can provide access to a searchable online portal with this information.
- Specific Rules for Active Pharmaceutical Ingredients (APIs): APIs (the core chemical components in drugs) must have labels or accompanying certificates of analysis that identify the original manufacturer. The "original manufacturer" is defined as the last facility that performed major production steps before the API enters interstate commerce.
- Specific Rules for Finished Drug Products: Labels for completed drugs (ready for use) must identify:
- The original manufacturer of each API used.
- The original manufacturer of the finished product.
- The packer or distributor, if applicable.
If a drug uses APIs from multiple manufacturers, all must be listed on the label or in the electronic portal.
- Accessibility of Information: Manufacturers must provide the required details in a package insert or as a paper copy upon request, in addition to electronic options.
- Implementation by FDA: The Secretary of Health and Human Services (through the FDA) must issue regulations to enforce these rules for APIs and finished products. Regulations can allow minor adjustments, such as electronic-only labeling in some cases. They take effect no earlier than one year after final publication and apply only to drugs made after that date.
- Customs Exemption: Finished drug products compliant with these labeling rules are exempt from standard U.S. customs requirements to mark the country of origin under the Tariff Act of 1930.
Significant Changes to Existing Law
- Expands Section 502(b) of the Federal Food, Drug, and Cosmetic Act (which previously required only basic manufacturer and content info on labels) to mandate supply chain details, including API origins—information not previously required.
- Introduces flexible electronic disclosure options (e.g., QR codes) alongside traditional labels, modernizing compliance.
- Adds a new exemption in the Tariff Act of 1930, relieving compliant drugs from country-of-origin marking at import, which simplifies customs processes but ties it directly to FDA labeling standards.
Potential Impacts
- On Government Agencies: The FDA gains new regulatory duties to develop and enforce rules, potentially increasing oversight of drug production. U.S. Customs and Border Protection may see reduced marking enforcement for compliant imports, streamlining border processes.
- On Citizens: Consumers benefit from clearer information on drug sources, aiding informed choices and enabling faster identification of contamination or counterfeit risks. This could enhance public health safety without adding direct costs to individuals.
- On International Relations: Foreign drug manufacturers exporting to the U.S. must comply with enhanced labeling, possibly affecting trade flows. The customs exemption could ease imports from compliant countries, but non-compliance might lead to barriers, promoting global supply chain standards.
Main Stakeholders Affected
- Pharmaceutical Industry: Manufacturers, packers, and distributors (especially those handling APIs or imports) must update labeling systems, potentially incurring compliance costs but gaining from standardized transparency.
- Consumers and Patients: Primary beneficiaries through better access to supply chain details, empowering them to verify drug authenticity.
- Regulatory Bodies: FDA for enforcement and rulemaking; U.S. Customs for import exemptions.
- Healthcare Providers: Gain tools to trace drugs in case of adverse events, improving response times.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens FDA authority over drug labeling without altering core safety standards, potentially aiding enforcement against adulterated or misbranded drugs. The one-year implementation grace period provides industry adjustment time, reducing litigation risks from abrupt changes.
- Constitutional: No apparent conflicts; aligns with Congress's commerce clause powers to regulate interstate drug trade and protect public health.
- Political: Bipartisan sponsorship (from senators across parties) suggests broad support for supply chain transparency, possibly in response to past drug safety concerns like shortages or foreign sourcing issues. It emphasizes accountability without imposing broad new taxes or restrictions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (11)
Sen. Gillibrand, Kirsten E. [D-NY], Sen. Tuberville, Tommy [R-AL], Sen. Britt, Katie Boyd [R-AL], Sen. Johnson, Ron [R-WI], Sen. Moody, Ashley [R-FL], Sen. Lee, Mike [R-UT], Sen. Cramer, Kevin [R-ND], Sen. Risch, James E. [R-ID], Sen. Grassley, Chuck [R-IA], Sen. Ricketts, Pete [R-NE], Sen. Ernst, Joni [R-IA]
Recent Actions
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- 2026-02-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-02-05: Introduced in Senate
Bill Versions
- Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act — issued 2026-02-05 — PDF (5 pages)